Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines

Most anticancer treatments carry a risk for infusion reactions (IRs); incidence may increase when different agents are administered concomitantly. IRs are either allergic reactions to foreign proteins [generally immunoglobulin E (IgE)-mediated allergic responses] or non-immune-mediated reactions [1]. Most IRs are mild with symptoms such as chills, fever, nausea, headache, skin rash, pruritus, etc. Severe reactions are less frequent and may be fatal without appropriate intervention.